The United Kingdom and the United States have agreed to a important commercial pact that will ensure zero duties on UK drug products going into the US market.
Key Provisions of the Accord
Under the terms of the agreement, the UK has committed to increase funding on drugs through the public health system. This pledge guarantees that tariffs on these vital products will stay at nothing for a duration of three years.
This agreement is in response to previous statements to significantly raise tariffs on branded pharmaceutical products, with figures floated reaching 100%.
"This agreement with the Britain bolsters the international landscape for new treatments and introduces long-overdue balance to U.S.–U.K. pharmaceutical trade," a release noted.
Trade Significance
Medicines represent one of the the United Kingdom's largest goods shipped to the United States, which is easily the largest destination for major companies like GSK and AstraZeneca.
Export figures indicate that in the year prior to the third quarter, the UK exported drugs totaling over eleven billion pounds to the US. This value accounted for a significant portion of British export trade in that period.
"This agreement protects jobs, increases capital expenditure and paves the way for the UK to become a worldwide center for biotech and pharma," a government official commented.
Detailed British Pledges
The pact entails several specific pledges from the UK:
- Higher Cost Ceiling: The UK will raise the price threshold at which it considers new treatments to be unaffordable by a quarter.
- Increased NHS Spending: There is a goal to double total NHS spending on treatments from 0.3 percent of the national economy to 0.6% over the coming ten years.
- Payback Limit: The sum manufacturers must pay back to the NHS to control costs will be capped at fifteen percent. In the past, repayments exceeded 20%.
Recent Tensions
The pact comes amid a ongoing row between the pharmaceutical industry and the UK government over medicine costs and approval rates.
This friction were exacerbated by assertions that American customers were charged a premium for the same drugs than people in the Britain and the EU.
Over the last 18 months, several large drug company projects in the UK have been delayed or abandoned, while major expansions have been announced toward projects in the United States.
The Science Minister stated that the NHS must increase expenditure on treatments, noting that its expenditure on drugs had declined as a share of its overall budget over the previous ten-year period.
